HomeArticlesServicePriceAbout

Over the past 8 weeks (from Jan 24 to Mar 21, 2025), analyst reports covering major S&P 500 companies revealed several stocks whose target prices were revised downward by more than 10%.

This is interpreted as a reflection of changes in company fundamentals, macroeconomic factors, and shifts in industry competition. From a sell-side perspective, such target price cuts may indicate short-term downside pressure, suggesting that investors should consider proper risk management and exit strategies.

Below are details of companies with target prices lowered by more than 10% compared to 8 weeks ago. Each company's target price as of Jan 24 and Mar 21, 2025, is provided, along with the percentage decrease.

1. AES (AES-US)

• Target Price (Mar 21, 2025): $15

• Target Price (Jan 24, 2025): $17

• Change: -11.8%

• Key Issue: Slowing growth in the power and utility sectors and rising energy costs are putting pressure on profitability.

2. Albemarle (ALB-US)

• Target Price (Mar 21, 2025): $98

• Target Price (Jan 24, 2025): $112

• Change: -12.5%

• Key Issue: Volatility in the lithium market—a key material for EV batteries—and concerns over economic slowdown have led to lowered sales growth expectations.

3. Advanced Micro Devices (AMD-US)

• Target Price (Mar 21, 2025): $145

• Target Price (Jan 24, 2025): $171

• Change: -15.2%

• Key Issue: Ongoing concerns around weakening demand in the PC and data center markets, along with intensified competition and macroeconomic uncertainty, are undermining short-term earnings momentum.

4. Brown Forman Class B (BF.B-US)

• Target Price (Mar 21, 2025): $40

• Target Price (Jan 24, 2025): $46

• Change: -13.0%

• Key Issue: Weak consumer demand and rising raw material costs are squeezing margins, while intensified global competition in the alcohol market is limiting growth prospects.

5. Biogen (BIIB-US)

• Target Price (Mar 21, 2025): $198

• Target Price (Jan 24, 2025): $228

• Change: -13.2%

• Key Issue: Uncertainty around the clinical results of new drugs and increased competition have led to lower sales estimates. Regulatory risks are also being cited as a potential concern.

While the reasons and extent of the target price downgrades vary by company, they broadly reflect macro-level risks such as recession concerns, supply chain issues, cost inflation, and intensifying industry competition. In some cases, structural changes in the respective industries (e.g., EV battery demand volatility, semiconductor market conditions) played a significant role.

From a sell-side strategy perspective, these stocks are likely to face near-term downward momentum. Investors should consider adjusting their portfolio exposures or evaluating short-position strategies. Volatility could also increase depending on upcoming earnings announcements, interest rate movements, and macroeconomic indicators, so a flexible approach aligned with market trends is essential.

[Compliance Note]

• All posts by Sellsmart are for informational purposes only. Final investment decisions should be made with careful judgment and at the investor’s own risk.

• The content of this post may be inaccurate, and any profits or losses resulting from trades are solely the responsibility of the investor.

• Core16 may hold positions in the stocks mentioned in this post and may buy or sell them at any time.